One interesting experimental strategy aimed at redirecting T cells against target cells involves engineering T cells with the CD16/gamma receptor gene, which can eliminate cancer cells in combination with an anti-TAA monoclonal antibody (mAb) produced by the ADCC [19]. Here, FCGR3A is linked to cancer.